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NeurodegenerationHormone-dependent aggregation of the androgen receptor (AR) with a polyglutamine (polyQ) stretch ampli-
ﬁcation (>38) is considered to be the causative agent of the neurodegenerative disorder spinal and bulbar
muscular atrophy (SBMA), consistent with related neurodegenerative diseases involving polyQ-extended
proteins. In spite of the widespread acceptance of this common causal hypothesis, little attention has been
paid to its apparent incompatibility with the observation of AR aggregation in healthy individuals with no
polyQ stretch ampliﬁcation. Here we used atomic force microscopy (AFM) to characterize sub-micrometer
scale aggregates of the wild-type (22 glutamines) and the SBMA form (65 glutamines), as well as a polyQ de-
letion mutant (1 glutamine) and a variant with a normal length polyQ stretch but with a serine to alanine
double mutation elsewhere in the protein. We used a baculovirus-insect cell expression system to produce
full-length proteins for these structural analyses. We related the AFM ﬁndings to cytotoxicity as measured
by expression of the receptors in Drosophila motoneurons or in neuronal cells in culture. We found that
the pathogenic AR mutants formed oligomeric ﬁbrils up to 300–600 nm in length. These were clearly differ-
ent from annular oligomers 120–180 nm in diameter formed by the nonpathogenic receptors. We could also
show that melatonin, which is known to ameliorate the pathological phenotype in the ﬂy model, caused
polyQ-extended AR to form annular oligomers. Further comparative investigation of these reproducibly dis-
tinct toxic and non-toxic oligomers could advance our understanding of the molecular basis of the polyQ
pathologies.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
SBMA belongs to a group of nine neurodegenerative diseases
termed polyQ disorders because they occur as a result of polygluta-
mine ampliﬁcations in different proteins [1]. A characteristic feature
of all these diseases is misfolding and aggregation of the mutant pro-
tein. SBMA is caused by ampliﬁcation of a polyQ stretch in androgen
receptor (AR) and like the other polyQ disorders, it is a late onset dis-
ease that could likely have arisen from a steady inclusion formation
process in the lifetime of the affected person. Inclusion formation is
clearly associated with neuronal cell death, because although the AR
is expressed throughout the central nervous system [2], nuclearndrogen receptor; DHT, dihy-
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l rights reserved.aggregates are exclusively found in the SBMA-affected spinal cord
and the brain stem [3]. The aggregate formation and pathology of
SBMA is strictly dependent on the presence of the androgen recep-
tor's physiological ligand dihydrotestosterone (DHT) [4]. Although
several putative models have been proposed, it is still unclear how
the polyQ stretch ampliﬁcations lead to neurodegeneration.
It is accepted that the main step in the pathogenesis of the polyQ
proteins is misfolding which leads to an altered function of the pro-
teins. The consequence of misfolding is the aggregation of the
polyQ-extended protein that becomes visible as intranuclear or cyto-
plasmic aggregates of the polyQ-extended proteins in neurons [5].
Initially large cytoplasmic and nuclear aggregates reaching sizes of
6 μm were suggested as a common pathogenic mechanism for all of
the polyQ disorders [6,7]. Subsequent studies have however strongly
suggested that these aggregates are neither necessary nor sufﬁcient
to initiate the polyQ-mediated disorders [8,9]. More recent studies
suggest that oligomeric species upstream of the large aggregates
with sizes of less than 1 μm are the toxic form [10]. These are believed
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ilar proposals for the identity of the toxic species have been made
with respect to other neurodegenerative diseases including Alzhei-
mer's and Parkinson's [11,12]. Indeed, current research is guided by
the assumption that a common mechanism of cytotoxicity underlies
all protein misfolding diseases [11], although application of such hy-
potheses to SBMA has the serious difﬁculty that a certain amount of
aggregation is seen regardless of whether the polyQ extension and
the pathological phenotype are present [6,13].
For an understanding of the molecular mechanism of cytotoxicity
in this group of diseases, knowledge not only of the identity of the cy-
totoxic species but also of its structure is clearly essential. The oligo-
mers are believed to be formed by extended β-sheets in the mutant
protein [14], which can lead to ﬁbrillar and also non-ﬁbrillar species
[15]. Nagai et al. could show that α-helical polyQ-monomers are not
toxic, whereas conformational changes following misfolding from
an α-helix to a β-sheet result in cellular toxicity [16]. This conforma-
tional transformation to β-sheet-rich amyloid-like structures, compa-
rable to polymerization reactions is a commonly accepted feature of
polyQ expanded proteins. However, there is still disagreement re-
garding the shape of these oligomers, with conﬂicting results from a
number of investigations [15]. A possible cause of these discrepancies
is that different sized fragments containing the polyQ stretches or ar-
tiﬁcial polyQ peptides were used for these studies. To avoid this issue,
in the present study we used full-length proteins with 1, 22 or 65 glu-
tamines for studies of oligomeric structure for the ﬁrst time.
In addition to the extended polyQ stretch, there are other genetic
and chemical factors that are known to modulate the pathological
phenotype in polyQ diseases. For example exchanges of acetylation
or phosphorylation sites outside an otherwise non-pathogenic
polyQ stretch can convert this protein into a toxic protein in the ab-
sence of an ampliﬁcation of the polyQ stretch [17,18], and melatonin
has been shown to be a chemical rescuer of SBMA when polyQ ampli-
ﬁcation is present [18]. It is not known whether such factors can pre-
vent or induce the formation of aggregates, or modulate the toxicity
of the aggregates formed, or exert their effects further downstream
in the pathway to cell damage. Clearly the investigation of this ques-
tion could shed more light on the molecular mechanism of toxicity.
In the present work we have studied full-length AR constructs
with polyQ stretches of normal (ARQ22) and pathological (ARQ65)
as well as a deletion mutant (ARQ1) and an ARQ22 mutant with ala-
nine substitutions for Ser424 and Ser514 (ARQ22dm), in each case in
the presence and absence of the physiological ligand DHT and/or the
pathological phenotype rescuer melatonin. For each combination of
construct and chemical modulators, the toxicity was evaluated with
a Drosophila model (survival, locomotion, neuromuscular junction
morphology), and the structure of the AR aggregates was investigated
by expression in a baculovirus system followed by isolation and mea-
surement with atomic force microscopy (AFM). We could show that
all of the toxic forms of the AR form a similar conformer. The non-
toxic forms of the receptor also form aggregates in the presence of
hormone but these are different in conformation from those formed
by the toxic forms of the receptor. The SBMA phenotype rescuer mel-
atonin changed the conformation of the aggregates from the toxic to
the non-toxic forms.
2. Materials and methods
2.1. Drosophila
2.1.1. Fly strains
pUAST-ARQ22 and pUAST-ARQ22dm have previously been de-
scribed [18]. pUAST-ARQ1 and -ARQ65 were generated according to
standard procedure by Drosophila Embryo Injection Services http://
www.thebestgene.com/. Transgenic ﬂy lines were crossed with
OK371-GAL4 driver. Maintenance of the ﬂy lines was carried outessentially as described by [18]. Larvae were treated with vehicle
alone (1.6% ethanol), with food containing an end concentration of
10−3 M DHT or 10−2 M melatonin dissolved in 80% ethanol. Immuno-
blotting of Drosophila lysates was performed as previously described by
Funderburk et al. [18] using anti-AR speciﬁc antibody AR 441 and α-
tubulin antibody (Santa Cruz Biotechnologies).
2.1.2. Larval locomotion
AR and OK371-GAL4 ﬂy lines were crossed on apple agar plates
and after hatching, 50 ﬁrst-instar progeny larvae were transferred
to standard medium containing vehicle (0.08% ethanol), 10v3 M
DHT, 10−2 M melatonin, or a combination of the latter two. After
5 days the number of pupae found on the wall of the food vial, indi-
cating normal locomotor ability, was counted and the ratio of wan-
dering larvae was calculated.
2.1.3. Immunohistochemistry
Dissected late third-instar larvae were ﬁxed in 4% paraformalde-
hyde and stained with the Cy™5-conjugated AfﬁniPure Goat Anti-
Horseradish antibody (1:200; Jackson Immunoresearch) to label neu-
ronal structures [19]. NMJ branches were counted using a Leica
DM5000 B ﬂuorescence microscope.
2.2. AR oligomer isolation
Sf9 cells were cultured in SF900 II (Invitrogen) medium supple-
mented with 5% fetal calf serum (FCS) at 27 °C with continuous shak-
ing at 110 rpm at a density of 109 cells. One day prior to infection, the
medium was changed to serum-free SF900 II medium. Cells were
infected with baculovirus stocks typically at MOIs of 5–7. 72 h post-
infection, cells were treated with 10−4 M DHT (ﬁnal concentration),
10−4 M melatonin, 10−4 M DHT and melatonin or an equivalent vol-
ume of the vehicle (0.001% ethanol) for 3 h. The infected SF9 cells
were lysed on ice in lysis buffer (20 mM HEPES pH 7.4, 400 mM
NaCl, 1 mM β-mercapto-ethanol, 1 mM ZnCl2, 1 mM PMSF, 1 mM
Na2V03, 10 μl protease inhibitor cocktail (RocheMannheim, Germany)
per ml) in the presence of 10−4 M DHT, 10−4 M melatonin, 10−4 M
DHT and melatonin or an equivalent amount of ethanol as control).
The lysates were then centrifuged at 14,000×g at 4 °C for 10 min. Iso-
lation of the biotin-tagged AR samples was performed on a streptavi-
din–mutein–matrix (Roche Mannheim, Germany) according to the
manufacturer's instructions at 4 °C.
2.3. Atomic force microscopy
10 μl (1–2 μg) of freshly isolated AR samples were spotted on mica
and allowed to attach to the surface for 1 min. The mica surface was
washed 10 times with 100 μl of distilled water to remove unbound
protein and impurities. Mica was then dried with gentle dry nitrogen
purge for 2 min. The samples were directly analyzed with Mikromash
NSC 15 ALB cantilevers on a Veeco Nanoscope III A (Veeco Mannheim,
Germany) in tapping-mode. Pictures were ﬂattened and analyzed
with Veeco V700 software version 3.2. Quantiﬁcations were per-
formed in Image J software. For Immuno-AFM studies, 50 μl of freshly
isolated AR samples were incubated with 20 ng/μl F39.4.1 anti-AR an-
tibody at 4 °C under continuous rotation for 30 min. Thereafter the
antibody or buffer treated samples were spotted on mica as described
above.
2.4. Cellular uptake studies and immunoﬂuorescence
SK-N-SH cells were cultured in Dulbecco's minimal Eagles' medi-
um (DMEM) (Invitrogen) supplemented with 10% FCS at 37 °C. 24 h
prior to the infection experiments the medium was changed to
DMEM supplemented with 3% charcoal stripped fetal calf serum.
Cells were cultured to a maximum conﬂuence of 70–80% and treated
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vehicle alone (0.001% ethanol). Cell viability was analyzed by CellTi-
ter blue cell assay (Promega Mannheim, Germany) according to the
manufacturer's instructions or by immunoﬂuorescence.
For immunoﬂuorescence, cells were cultured on Lab-Tek 4-
Chamber-Slides (Thermo Fisher Langenselbold, Germany) and ﬁxed
with 4% paraformaldehyde. AR was detected with primary antibody
F39.4.1/Alexa-488 anti mouse (DAKO Diagnostica Hamburg, Germa-
ny) secondary antibody (Santa Cruz Heidelberg, Germany). Nuclear
staining was performed with 4′,6-Diamidin-2-phenylindo (DAPI)
(Invitrogen, Karlsruhe Germany) according to the manufacturer's in-
structions and the samples were examined by confocal microscopy by
visualizing 5 focal planes of the SK-N-SH inner nuclei on an LEICA SPE
LSM (Leica Microsystems Mannheim, Germany) with 63 times mag-
niﬁcation. Laser excitation was adjusted for all samples to a level at
which no Alexa-488 background signal was detected.2.5. Fluorescence polarization assay
The PolarScreen™ Androgen Receptor Competitor Assay, Green
(Invitrogen) was used to determine whether melatonin could bind
to the ligand binding domain (LBD) of the AR. The assay was per-
formed according to manufacturer's protocol. In brief, 25 nM AR-
LBD and 1 nM Fluormone™ AL Green were incubated for 4 h at
room temperature together with known concentrations of dexameth-
asone, DHT or melatonin. Fluorescence polarization was measured in
a Tecan F200 reader with 485 nm excitation and 535 nm emission in-
terference ﬁlters.3. Results
3.1. Drosophila model of SBMA
To determine the features that contribute to the toxicity of an AR
with or without a polyQ stretch ampliﬁcation, we used the GAL4-
UAS system [20] to express different AR mutants in the motoneurons
of the Drosophila larvae. We used the double serine to alanine ex-
change at the N-terminus of the wild-type AR described in our previ-
ous studies [18] and compared it with AR containing different lengths
of Q stretches (1, 22 and 65). We then analyzed the ability of the
transgenic larvae to crawl up the walls of their food vials (which we
refer to below as locomotor ability) and we examined possible abnor-
malities at the neuromuscular junction (NMJ) in the absence and
presence of the androgen DHT. All these assays were also carried
out in the presence of melatonin, a chemical rescuer of the SBMA in
the ﬂy model [18].
We could show in these studies that all of the AR constructs were
expressed in the transgenic Drosophila (Fig. 1a). In the behavioral
analysis, we could demonstrate that while no overt phenotype was
observed in larvae expressing ARQ22 and ARQ1 in the absence and
presence of DHT, a signiﬁcant reduction of locomotion was observed
in the presence of DHT in larvae expressing ARQ65 and ARQ22dm
(Fig. 1b and c). These latter two transgenic larvae also showed NMJ
abnormalities represented by noticeably reduced branching of the
axons in the presence of DHT (Supplementary Fig. S1a, b and
Fig. 1d, e). None of these abnormalities were seen in the ARQ1 and
ARQ22 transgenic lines, nor were they observed in the presence of
melatonin (Fig. 1b–e). Melatonin in the absence of DHT did not
have any effect on the transgenic larvae (Fig. 1b–e). These results
demonstrate that the wild-type AR with a polyQ stretch of 22 bearing
two amino acids exchanges outside the polyQ tract behaves in a sim-
ilar way as one with the polyQ stretch ampliﬁcation of 65. Thus the
toxicity attributed to polyQ stretch ampliﬁcation in the motoneurons
could also be generated by other changes in the AR.3.2. Oligomeric structures
Since misfolding and aggregation of AR with expanded polyQ
stretches are proposed as the main contributors to toxicity and physio-
logical defects, yet aggregation also occurs in wild-type AR, we exam-
ined the structure of the wild-type and mutant AR aggregates for
possible differences. We produced the receptors using a baculovirus-
insect cell expression system that is able to yield large amounts of pro-
tein to allow detailed analysis of structure–function relations and that
has successfully been used for functional analysis to study mutations
in the AR [21].
The receptors were isolated from baculovirus infected cells by a
single step afﬁnity chromatography procedure essentially as de-
scribed by Juzumiene et al. [22]. Coomassie blue staining of the eluted
material from the afﬁnity chromatographic step on SDS polyacryl-
amide gel electrophoresis clearly identiﬁed the receptors derived
from the DHT treated Sf9 cells (see asterisks in Fig. 2 for the recep-
tors). In the absence of hormone, the receptors were less stable, and
were not readily identiﬁable in the Coomassie blue stainings. Western
blot analysis showed that in the presence of DHT, apart from the full-
length receptor at approximately 110 kDa (ARQ1, ARQ22, ARQ22dm)
and 120 kDa (ARQ65), other AR proteolytic fragments were also elut-
ed andwere identiﬁed by the N-terminal AR speciﬁc antibody (Fig. 2).
Some of these proteolytic fragments observed in the cell lysate were
no longer identiﬁed after the chromatographic step possibly because
of the loss of the N-terminal biotin tag for binding to the streptavidin
matrix in the isolation procedure. Proteolytic fragments of the AR are
very important features of the aggregation [23,24] and some of the
ones identiﬁed in this work may play a role in this process.
We then determined the morphology of the receptors by AFM.
AFM scans of all the receptor preparations showed small globular
oligomers with heights of less than 10 nm and diameters of approx.
20 nm as well as large globular oligomers with heights between 12
and 20 nm and diameters between 40 and 70 nm (Supplementary
Fig. S2a). Quantiﬁcation of these oligomers showed that DHT treat-
ment signiﬁcantly reduced the number of the smaller oligomers but
increased the number of the larger oligomers of ARQ1 and ARQ22
(Supplementary Fig. S2b). The number of the smaller and larger olig-
omers of ARQ65 and ARQ22dm was not affected by hormone treat-
ment (Supplementary Fig. S2b). In addition to these changes,
treatment of the AR samples with androgens induced two additional
much larger types of aggregates. The ARQ1 and ARQ22 formed annu-
lar oligomers of diameters from 120 to 180 nm made up of several
subunits with average heights of 5 nm but with one subunit of
approx. 10 nm overarching the average height (Fig. 3a). The ARQ65
and ARQ22dm, on the other hand, formed ﬁbrils of 300–600 nm in
length and height of 5–10 nm (Fig. 3b). The oligomeric subunits at
the termini measure 10–20 nm in height. Whether the annular and ﬁ-
brillar oligomers are formed by a process that brings together the
smaller and larger globules in circular or linear arrangements is not
known. Quantiﬁcation of these ﬁbrillar and annular aggregate struc-
tures conﬁrmed their very highly statistically signiﬁcant dependence
on the presence of hormone (Fig. 3c).
To conﬁrm that the annular and ﬁbrillar oligomers contain the AR,
we incubated the receptor preparation with an antibody against the
AR prior to the AFM measurements. Binding of the AR antibody to
the oligomeric structures is expected to produce changes in shape,
height or width of the aggregates [25]. In the AFM pictures, signiﬁcant
differences could indeed be seen in these oligomers following treat-
ment with the AR antibody. Notably the lumen in the annular struc-
ture was closed and the ﬁbrillar oligomer shape was also altered
(Fig. 3d). Measurements and statistical analysis showed signiﬁcant
increases in both height and width of the aggregates attributable to
the binding of the antibody to these oligomeric structures (Fig. 3d).
The overall annular and ﬁbrillar shapes of the aggregates were how-
ever maintained following treatment with the antibody.
Fig. 1. Characterization of transgenic Drosophila larvae expressing mutant androgen receptor. Transgenic ﬂy lines used in this work were generated by crossing pUAST-AR lines
with OK371-GAL4 driver line. (a) Western blot analysis was carried out with 50 μg of lysate from 50 Drosophila heads using anti-AR speciﬁc antibody and α-tubulin speciﬁc anti-
body as a loading control. (b) and (c) Locomotion analysis of third-instar Drosophila larvae expressing ARQ22, ARQ65, ARQ1 and ARQ22dm in motoneurons. 50 ﬁrst-instar larvae
were transferred to medium containing vehicle (ethanol), 10–3 M DHT, 10–2 M melatonin, or a combination of both. The percentage of larvae which was found to crawl out of the
food vial was calculated. Data are obtained from three independent experiments. The error bars represent standard error of the mean. *pb0.05, ***pb0.001. (c) and (d) Third-instar
larvae expressing ARQ22, ARQ65, ARQ1 and ARQ22dm treated with vehicle (ethanol) or with DHT, melatonin or both were used for immunohistochemistry. Morphological analyses
were carried out on the NMJ on muscles 6 and 7 of the 4th abdominal segment stained with the Cy™5-conjugated AfﬁniPure goat anti-horseradish antibody. The NMJ morphology
was analyzed with a Leica DM5000 B ﬂuorescence microscope and the branches were counted. The bar chats show the average number of branches per muscle pair and the error
bars represent S.E.M. *pb0.05, ***pb0.001, n=9–15 branches.
Fig. 2. Receptor production and isolation. 109 SF9 cells were infected with recombinant baculoviruses (ARQ1, ARQ22, ARQ65 and ARQ22dm) and treated for 3 h with 10−4 M DHT.
An aliquot of the cell lysate (CL) was kept and the AR was isolated on a streptavidin–mutein–matrix. 60 μg of the AR samples (P) and the aliquot from the cell lysates were loaded on
a 10% SDS-PAGE and subjected to Western blot analysis. AR was detected using an anti-AR speciﬁc antibody, F39.4.1 antibody (Biogenex, Freemont CA USA) against the N-terminus
of the receptor and proteins on the membrane were visualized after Coomassie brilliant blue staining.
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Fig. 3. Identiﬁcation of AR morphology with atomic force microscopy. 1–2 μg of freshly isolated AR preparations from the biotin-streptavidin afﬁnity chromatography were directly
spotted on the freshly cleaved mica surface and investigated on a multimode Nanoscope III A (Veeco) in tapping mode. (a) High resolution scans of the ARQ1 and ARQ22 prepa-
rations. Scale bars represent 65 nm for ARQ1 and ARQ22. Heights are indicated by the color scale. Shown below is a representative measurement of the cross-sections of annular
oligomers analyzed by the AFM software (V700 version 3.0, Veeco). (b) High resolution scans of the ARQ65 and ARQ22dm preparations. Scale bars represent 115 nm for the re-
ceptors. Heights are indicated by the color scale. Shown below are representative measurements of the cross and longitudinal sections of the oligomeric ﬁbrils analyzed by the
AFM software (V700 version 3.0 Veeco). (c) Quantiﬁcation of the AFM measurements from 2 to 4 independent isolations of the AR analyzed by AFM where oligomers from 3
scans of 9 μm2 sizes for each experiment were accumulated and analyzed with the ImageJ software (http://rsbweb.nih.gov/ij). The aggregates counted were restricted to 1000
counted particles in each case. The bar charts represent average values with error bars S.E.M. *pb0.05; **pb0.001. (d) Immuno-AFM to identify the AR as a component of the olig-
omers. Prior to AFM analyses, the AR samples were divided into two portions. One half was incubated with 20 ng F39.4.1 antibody/μl protein solution the other half with an equiv-
alent volume of buffer as control. 3–5 μg of the samples were directly spotted on the mica surface and investigated with the AFM in tapping mode. Cross-sections and heights of
antibody treated annular oligomers and oligomeric ﬁbrils or control treated samples were analyzed by the AFM software (V700 version 3.0, Veeco). Scale bar represents 65 nm
for ARQ22 and 115 nm for ARQ65 and the heights are indicated by the color scale. The results are quantiﬁed and presented below as bar charts representing the average values
with error bars S.E.M. *pb0.05; **pb0.001.
1074 T. Jochum et al. / Biochimica et Biophysica Acta 1822 (2012) 1070–10783.3. Melatonin inﬂuences oligomeric structure of the AR
As melatonin decreases toxicity of the mutant AR in the ﬂy model,
we investigated whether it exerts its effect through alteration of the
morphology of the oligomers. We treated the Sf9 cells with DHT in
combination with melatonin or melatonin alone prior to the receptor
isolation and analyzed the samples with AFM. Treatment of the Sf9
cells expressing the wild-type and mutant AR with melatonin did
not result in any obvious change in the morphology of the DHT-
independent small and large globular aggregates seen in the receptor
preparation (Supplementary Fig. S2c). However, melatonin-mediated
formation of annular structures were seen in cells expressing ARQ22
albeit the number of annular aggregates was slightly reduced com-
pared with that formed in the presence of DHT (Fig. 4a). Treatment
with melatonin in the presence of DHT did not change theaggregation quality of ARQ22 except that it reduced the number of
annular structures formed by this receptor (Fig. 4a). In contrast, treat-
ment of the cells expressing ARQ65 with melatonin alone or melato-
nin plus DHT led to the formation of annular aggregates which were
not observed with DHT alone in this mutant receptor preparation
(Supplementary Fig. S2c and Fig. 4a). More importantly, the number
of ﬁbrillar oligomers formed by the ARQ65 in the presence of DHT
was drastically reduced by melatonin, although melatonin alone in-
duced the formation of a few ﬁbrillar structures from ARQ65 (Supple-
mentary Fig. S2c and Fig. 4b). The fact that melatonin trigged the
formation of oligomers on its own indicates that this hormone does
not prevent the formation of aggregates but rather changes the
types of oligomers that are produced.
To determine whether the melatonin-induced changes in oligo-
meric structure of the AR affect the toxicity of the receptor in the
DHT DHT/M M DHT DHT/M M
0
5
10
15
A
O
s 
pe
r 1
03
 
pa
rti
cl
es
*
***
ARQ22 ARQ65
DHT DHT/M M DHT DHT/M M
0
1
2
3
FO
s 
pe
r 1
03
 
pa
rti
cl
es
*
*
ARQ22 ARQ65
a b c
d
- + - +
0
5
10
15
20
25
po
si
tiv
e 
ce
lls
 (%
) **
ARQ22 ARQ65
DHT
0
60
80
100
ce
ll 
vi
ab
ili
ty
 (%
) ***
**
**
Sf9 ARQ22 ARQ65 ARQ22dm
CTRL
DHT M
DHT/M
e f
g h
control EtOH DHT
0
20
40
60
80
100
120
ce
ll 
vi
ab
ili
ty
 (%
)
ARQ22 D
ARQ65 D
*
ns
ARQ22 D/M
ARQ65 D/M
***
*
control - + - + - +
0
20
40
60
80
100
ce
ll 
vi
ab
ili
ty
 (%
)
*
**
ARQ22
DHT
ARQ65 ARQ22dm
*
*
Fig. 4.Melatonin as a modiﬁer of oligomer morphology and toxicity. Human neuronal SK-N-SH cells were cultured in the absence and presence of 10−7 M DHT for 24 h with 3.5 nM
AR obtained from the baculovirus expressed system in the presence of DHT. (a, b) The effect of melatonin on AR oligomers. 109 Sf9 cells were infected with recombinant baculo-
viruses (ARQ22 and ARQ65) and treated for 3 h with 10−4 M DHT, DHT and melatonin or melatonin. Cells were lysed and the AR isolated on the streptavidin matrix. 1–2 μg freshly
isolated samples were directly spotted on a mica surface and investigated on a Multimode Nanoscope III A in tapping mode. AFM measurements were quantiﬁed. 3–4 independent
experiments were conducted and the annular oligomers (AOs) (a) and ﬁbrillar oligomers (FOs) (b) from 3 scans of 9 μm2 sizes for each experiment were counted with the Image J
software. Data were restricted to on 1000 counted over all particles. Statistics: error bars S.E.M/ *pb0.05; **pb0.001; ***pb0.0005. The effect of the different AR constructs and treat-
ments directly in the Sf9 cells. (c) Level of AR expressed in Sf9 cells following infection with AR baculoviruses. Cells were infected with baculoviruses of ARQ22, ARQ65 and ARQ65 at
the same MOI. 72 h after infection the cells were lysed and cellular proteins were loaded on a 10% SDS-PAGE and subjected to Western blot analysis with an anti-AR speciﬁc an-
tibody F39.4.1 antibody and an anti-α-tubulin antibody as a control for equal amount of protein loaded on the gel. (d) Effect of the expression of AR mutant on cell viability in
the presence of DHT and melatonin. Sf9 cells expressing equal levels of ARQ22, ARQ65 and ARQ22dm were treated for 24 h with 10-4 M DHT, DHT and melatonin, melatonin or
an equivalent volume of the vehicle ethanol and subsequent cell viability was analyzed using a CellTiter Blue cell viability assay (Promega Mannheim, Germany). Shown as bar
charts are percentage viable cells from the average of 2–4 independent experiments±S.E.M *pb0.05; **pb0.001; ***pb0.0005. (e) Western blot to show the effect of DHT and mel-
atonin on AR stability. Western blot experiment was performed on the samples from (d) following 24 h treatment with DHT and melatonin. AR was detected using an anti-AR spe-
ciﬁc antibody F39.4.1 antibody and anti-α-tubulin antibody as a control for equal amount of protein loaded on the gel. (f) Cellular uptake of the AR oligomer samples was
determined by confocal microscopy of the inner nuclear focal planes (see Supplementary Fig. 2). For each experiment 200 cells were analyzed for cellular uptake of AR oligomers.
Dataset is based on 3 independent experiments. Statistics: error bars S.E.M. **pb0.001. (g) (h) Cell viability of AR oligomer-treated human neuronal SK-N-SH cells. The indicated AR
preparations were used to treat SK-N-SH cell in the absence and presence of 10−7 M DHT for 24 h. In (g), AR preparations in the presence of DHT were used. In (h), the Sf9 cells
were treated with DHT (D) or DHT and melatonin (D/M) before isolation of the receptor and subsequent application to the SK-N-SH cells. Thereafter CellTiter Blue cell viability
assay (Promega Mannheim, Germany) was carried out. Cell viability was normalized on the controls treated with protein buffer. Statistics: Experiments were done in triplets
with 2–4 independent repeats; error bars S.E.M/ *pb0.05; **pb0.001; ***pb0.0005.
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affected the viability of the cells. Three days after infection of the cells
with ARQ22, ARQ65 and ARQ22dm baculoviruses, the cells were trea-
ted with DHT, DHT plus melatonin or melatonin alone for 24 h and
the viability of the cells were assessed with CellTiter-Blue viability
assay. Prior to the hormone treatment, Western blot analysis showed
almost equal amount of receptor expression in the infected cells
(Fig. 4c). DHT and melatonin did not have any signiﬁcant effect on
the viability of the un-infected Sf9 cells or cells infested with ARQ22
baculovirus (Fig. 4d). In contrast, DHT treatment resulted in asigniﬁcant reduction in viability of cells infected with ARQ65 and
ARQ22dm baculoviruses (Fig. 4d). As in the case of the Drosophila
model, the negative effect of DHT was abolished by melatonin treat-
ment although more strongly in the ARQ65 than the ARQ22dm
infected cells (Fig. 4d). Melatonin alone did not have any noticeable
effect on the viability of these cells (Fig. 4d). The effect of DHT on
cell viability or the rescue action of melatonin did not alter the stabil-
ity of the AR as determined by Western blot experiments (Fig. 4e).
We then determined whether the receptor oligomers isolated
from the infected Sf9 cells are still capable of exerting toxic effect
1076 T. Jochum et al. / Biochimica et Biophysica Acta 1822 (2012) 1070–1078when applied exogenously to cells. To determine this, we made use of
the concept that polyQ oligomers and artiﬁcial polyQ peptides can be
taken up by cells in culture and can affect cell survival [26,27]. We
treated human neuronal SK-N-SH cells with the ARQ22 and ARQ65
samples isolated from hormone treated Sf9 cells as a test case of sam-
ples that contain annular and ﬁbrillar oligomers. The SK-N-SH cells
themselves were incubated with and without DHT and the presence
of the AR was determined by confocal microscopy in the inner focal
plane of the nucleus. We could show that the AR oligomers were
readily taken up by the neuronal cells after 24 h of incubation and re-
sided either in the cytoplasm or in the nucleus of the cells (Supple-
mentary Fig. S3). Furthermore we could show that while there was
no difference in the uptake of the ARQ22 preparation in the absence
and presence of hormone, the cellular uptake of the ARQ65 prepara-
tion occurred slightly more readily in the presence of DHT than in
the absence of hormone (Fig. 4f). The reason for this difference is
not known but may reﬂect an effect of the morphology of the aggre-
gates on the cellular uptake mechanism. CellTiter-Blue cell viability
studies on cells that had ingested the AR oligomers revealed reduced
survival of cells incubated with ARQ65 or ARQ22dm samples contain-
ing the oligomeric ﬁbrils as compared to the ARQ22 samples with the
annular oligomers. This effect was independent of the treatment with
hormone (Fig. 4g), which indicates that the primary action of the hor-
mone is in causing the formation of the ﬁbrillar and annular oligo-
mers. Once the pathologic structures have been formed, these are
responsible for reducing the survival of the cells and the hormone
has no further inﬂuence on overall cell survival.
We further determined whether ARQ65 isolated from Sf9 cells
treated with DHT and melatonin would impact the toxicity of these
oligomers on the SK-N-SH cell. AR22 and ARQ65 oligomers were iso-
lated from Sf9 cells following treatment with DHT, DHT and melato-
nin or melatonin alone and these were used to infect SK-N-SH cells
in the absence and presence of DHT. Twenty four hours after the
infection, cell viability studies were carried out as previously de-
scribed. These studies showed that ARQ22 oligomers from DHT
and/or melatonin-treated Sf9 cells did not show any effect on neuro-
nal cell viability whereas ARQ65 oligomers isolated from the DHT
treated Sf9 cells were toxic independent of the hormone treatment
of the SK-N-SH cells (Fig. 4h) as we have shown in Fig. 4g. More
importantly, ARQ65 oligomers from DHT and melatonin or melato-
nin treated Sf9 cells were no longer toxic in the neuronal cells
(Fig. 4h). These experiments together show that DHT exerts a toxic
effect on ARQ65 and ARQ22dm both in the Sf9 cells or when isolated
and used exogenously to treat SK-N-SH cell and melatonin rescues
the effect of DHT in both situations.
3.4. Action of melatonin on the AR
To ﬁnd out the mechanism by which melatonin affects AR action,
we determined whether melatonin binds to the AR. We considered
a direct interaction of melatonin with the AR a possible mode of ac-
tion since, like DHT, it can also affect the morphology of the receptor
albeit far less efﬁciently than DHT (Fig. 4a and b) and additionally it
can make the ARQ65 form annular oligomers (Fig. 4a). We therefore
carried out a ﬂuorescence polarization experiment in which melato-
nin was used to displace binding of a Fluormone™ AL Green ligand
from the ligand binding domain (LBD) of the AR. While DHT efﬁcient-
ly displaced the Fluormone, melatonin or dexamethasone (as a nega-
tive control) was unable to displace the ligand (Fig. 5a). This is
consistent with the hypothesis that melatonin does not directly
bind the LBD of the AR and its action is most likely indirect.
A possibility however still exists for melatonin to interact with
other parts of the receptor aside from the LBD. A further possibility
exists for it to indirectly affect the action of the AR through post-
translational modiﬁcation following binding to its cognate receptors
at the plasma membrane. We therefore used the Sf9 cells expressingthe ARQ22, AGQ65 and AQ22dm to compare the ability of melatonin
with DHT to phosphorylate two of the several androgen-mediated
phosphorylation sites described on the AR (serine 210/213 and serine
308) [28]. Intriguingly, melatonin behaved in a similar way in phos-
phorylating the two sites analyzed. (Fig. 5b and c) indicating that,
like DHT, melatonin can also affect post-translational modiﬁcation
of the AR. It remains to be seen whether differences exist in the
melatonin- and DHT- mediated phosphorylation of other sites on
the AR to account for their different effects on the morphology of
the mutant ARs.
4. Discussion
The major new ﬁnding of this work is that the toxicity associated
with the 65 residue polyQ extension in AR is reﬂected in an altered
oligomerization process leading to a ﬁbrillar oligomer form, rather
than the annular form produced by wild-type ARQ22. The depen-
dence of a pathological phenotype on the presence of the polyQ ex-
tension could be conﬁrmed for the constructs used in this study by
expression in Drosophila motoneurons, and moreover the toxicity of
the ARQ65 ﬁbrils, but not of the ARQ22 annuli, was demonstrated fol-
lowing internalization of these oligomers in human neuroblastoma
cells. The internalization of these oligomers is consistent with recent
ﬁndings that large aggregates composed of synthetic poly Q peptides
(tagged or untagged) can be taken up by cultured cells [26,27,29]. The
observation that both of the large oligomeric structures in our study
were formed only after treatment with the receptor's physiological li-
gand DHT is also consistent with the known dependence of pathology
of SBMA on the presence of this hormone [4]. The presence of AR in
both the ﬁbrillar and annular aggregates could be conﬁrmed by anti-
body labeling.
The non-toxic annular structures reported here for the ﬁrst time
are not to be confused with the annular protoﬁbrils (APF) that have
been reported in a number of neurodegenerative diseases [30]. Not
only are APFs much smaller (8–25 nm diameter), they are also postu-
lated to be the central cytotoxic species in these diseases. The only
observation that we are aware of that seems in some way comparable
to our ﬁndings are the 40–100 nm diameter, non-toxic annular aggre-
gates formed by the Parkinson's disease protein α-synuclein after
treatment with selegiline [31]. This has clear parallels with the forma-
tion of non-toxic annular oligomers of ARQ65 on treatment with mel-
atonin, which is the ﬁrst demonstration of such a phenomenon in a
neurodegenerative disease other than Parkinson's. Moreover, our ob-
servations show for the ﬁrst time that such annular structures can be
induced by protein sequence differences as well as by chemical treat-
ment, and in the case of ARQ22 in fact are formed by the wild-type
form of the protein.
Although the issue has been little addressed in the literature, the
fact that aggregation of AR occurs regardless of whether the polyQ ex-
tension and the pathological phenotype are present [6,13] until now
was difﬁcult to reconcile with the assumption that aggregation
plays a role in the pathology of SBMA. Our discovery of distinct
toxic and non-toxic oligomer forms now resolves this issue and thus
allows acceptance of the working hypothesis that the polyQ diseases
including SBMA have a common pathological mechanism.
The discovery of these toxic and non-toxic aggregate forms clearly
opens the possibility of comparative studies of their structure, prop-
erties and reactions as a promising approach to the still unresolved
central issue of how aggregates of polyQ-extended proteins cause cel-
lular damage, and this research direction will surely be exploited in
the future. However, some relevant observations can already be
made at this time on the basis of the AFM data reported in the present
work. It is notable that the lengths of the ﬁbrils approximate the cir-
cumference of the annular oligomers, and the taller subunits at the
termini of the ﬁbrils are reminiscent of the single taller subunit seen
in the annuli. It therefore appears that the toxicity of the ﬁbrils
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Fig. 5. Action of melatonin. (a) PolarScreen™ AR competitor assay, Green (Invitrogen) was used to determine binding of melatonin to the LBD of the AR. The assay was performed
according to manufacturer's protocol with the indicated concentrations of dexamethasone, DHT or melatonin. Fluorescence polarization shown are the curves from the average of
three different experiments. (b and c) Effect of melatonin on AR phosphorylation. Phosphorylation status of AR produced in SF9 cells with the baculovirus system. The baculovirus
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presumably due to constraints in the protein molecule, prevents tox-
icity by rendering the relevant structures inaccessible.
Our data show that the polyQ deletion mutant ARQ1 also formed
annular oligomers in the presence of DHT and was shown to be non-
toxic in theDrosophilamodel. In addition to reinforcing the conclusion
that non-toxicity is attributable to a speciﬁc oligomeric form, this re-
sult clearly shows that a polyQ stretch is not a requirement for oligo-
mer formation. This suggests that the polyQ stretch itself may not be
directly involved in the oligomerization of ARQ22, and thus calls into
question to what extent studies of artiﬁcial polyQ peptides [32–34]
can shed light on the oligomerization process of the full AR protein.
With the same Drosophila model, we were able to demonstrate
that mutation of two amino acids outside the polyQ stretch of AR
(Ser424 and Ser514 to alanine) caused the same reduced locomotor
activity and defects at the NMJ as the polyQ stretch ampliﬁcation.
Ser514 has been shown to be a phosphorylation site [35], while for
Ser424 this has yet to be conﬁrmed. Modulation of the pathological
behavior of AR by mutation of post-translational modiﬁcation sites
outside the polyQ stretch has already been reported, albeit not yet
for these particular two residues. There has been a report of a wild-
type receptor mimicking characteristics of a polyQ expanded AR fol-
lowing amino acid exchanges at acetylation sites outside the polyQ
stretch (Lys632 and Lys633 to alanines) [17], and in another report,
amino acid exchanges of two phosphorylation sites (Ser215 and
Ser792 to alanines) had no effect on the wild-type AR but the same
changes in an ARQ65 reduced the toxic effects of this receptor [36].However, until now there was no information available as to how
such mutations modulate toxicity. The data presented here show con-
clusively that the mode of action of the double serine to alanine mu-
tation is by modifying the oligomerization process of ARQ22 so as to
produce the same ﬁbrillar toxic aggregates as observed with ARQ65.
Further investigations into how these polyQ-external residues affect
the formation of toxic oligomers would appear to be a promising di-
rection for future studies.
A further important ﬁnding of this present work is the explanation
of the protective properties of melatonin. We had already reported
that melatonin rescues the pathological phenotype caused by the ex-
pression of polyQ-extended AR and ARQ22dm in a Drosophila model
[18], but the mode of action remained unclear: melatonin could be
preventing oligomerization of AR as has been observed in Alzheimer's
disease [37] or modulating the toxicity of the oligomers formed, or
exerting a protective effect further downstream on the pathway to
cell damage. The AFM data presented here show conclusively that
the second of these possible explanations is the case, since in the
presence of melatonin and DHT both ARQ65 and ARQ22dm formed
the same annular oligomers as those observed for the non-toxic
ARQ22 and ARQ1. The competition experiments reported here
showed that the effect of melatonin on AR does not occur through a
direct interaction with the ligand binding domain of AR. The effect
of melatonin on aggregation of the receptor therefore is either
through an interaction elsewhere on the AR molecule or is an indirect
effect through, for example, post-translational modiﬁcations of the
receptor.
1078 T. Jochum et al. / Biochimica et Biophysica Acta 1822 (2012) 1070–1078To summarize our main ﬁndings: sub-micrometer aggregates of
AR exist in two forms, a ﬁbrillar toxic form and an annular non-
toxic form; the observation of aggregates in healthy individuals
with no polyQ-extended AR therefore does not refute the hypothesis
that all polyQ diseases have a common, aggregation-related cause.
When AR toxicity is modulated by melatonin treatment or by muta-
tions outside the polyQ stretch, the mode of action in both cases is
by changing the type of AR aggregate produced.
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